SAB Biotherapeutics, Inc. (SABSW)

US — Healthcare Sector
Peers: SABS  JSPRW  NRXPW  ROIVW  SRZNW 

Automate Your Wheel Strategy on SABSW

With Tiblio's Option Bot, you can configure your own wheel strategy including SABSW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SABSW
  • Rev/Share 0.0407
  • Book/Share 2.304
  • PB 0.8334
  • Debt/Equity 0.3169
  • CurrentRatio 1.6882
  • ROIC -1.4315

 

  • MktCap 17840064.0
  • FreeCF/Share -3.4026
  • PFCF -0.5643
  • PE -0.5205
  • Debt/Assets 0.1779
  • DivYield 0
  • ROE -1.0514

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About SAB Biotherapeutics, Inc. (SABSW)

  • IPO Date 2021-10-25
  • Website http://www.sabbiotherapeutics.com
  • Industry Biotechnology
  • CEO Mr. Samuel J. Reich
  • Employees 63
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.